Dark

Check out our API

NYMX
Nymox Pharmaceutical Corp
stock NASDAQ

Inactive

Jul 6, 2023

0.2000USD-19.679%(-0.0490)932,736

Pre-market

0.00USD-100.000%(-0.25)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 25, 2022

09:32AM EST NYMOX Granted U.S. Patent #11,231,421 'Methods of treating multifocal cancer' Benzinga

Jan 3, 2022

07:21AM EST The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.15 A.M. ET). RTTNews

Dec 13, 2021

09:32AM EST Nymox Says Has Completed All Required Tasks In Preparation For Planned Upcoming Regulatory Submission For Fexapotide Triflutate Benzinga

09:30AM EST Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleasedto announce that it has completed all the Companys required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH. GlobeNewswire Inc

Nov 15, 2021

11:39AM EST Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to report today that it will bepresenting at theTorrey Hills Capital Emerging Growth Conference this week.The two-day conference is being held in San Diego, California. GlobeNewswire Inc

Oct 11, 2021

10:31AM EDT UPDATE: Nymox Pharmaceutical CEO Says 'main delayed vendor documentation that was incomplete has been accomplished' Benzinga

10:30AM EDT NYMOX Provides Current Update Benzinga

10:30AM EDT Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to report today a one-month update to shareholders as a follow-up to the September communication. The Company reinforces that itscompletiontasks for the important Fexapotide filing have advanced as anticipated and that substantial progress has ensued. GlobeNewswire Inc

Sep 10, 2021

09:32AM EDT NYMOX Provides Shareholder Update Benzinga

09:30AM EDT Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate. GlobeNewswire Inc

Aug 18, 2021

05:57AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 5.32 A.M. EDT). RTTNews

Aug 13, 2021

01:42PM EDT Nymox Pharmaceutical Q2 EPS $(0.05) Down From $(0.04) YoY Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 6, 2021

01:31PM EDT Nymox Announces Date For Fexapotide Filing; Will File For Marketing Approval Before End Of Summer, On Or Before Sept. 15, 2021 Benzinga

01:30PM EDT Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021. GlobeNewswire Inc

Apr 28, 2021

08:30AM EDT Nymox Announces $8,000,000 Private Placement GlobeNewswire Inc

Mar 29, 2021

09:20AM EDT Nymox Provides New Update on Regulatory Activities GlobeNewswire Inc

Nov 16, 2020

10:02AM EST Nymox Pharma Reports No Material Changes To Content Of Planned Applications For Its Benign Prostatic Hyperplasia Treatment; Says Unavoidable Delays Have Been Incurred But Co. 'Highly Confident' Filings Will Occur In Near-Term Horizon, Likely In Q1'21 Benzinga

10:00AM EST Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications. GlobeNewswire Inc

Aug 12, 2020

09:25AM EDT Nymox Announces $9 Million Registered Direct Offering GlobeNewswire Inc

09:13AM EDT Nymox 6-K Filing Shows $9M Registered Direct Offering Benzinga

Jul 28, 2020

09:34AM EDT Nymox Pharma Offers Update On Current Developments Benzinga

09:30AM EDT NYMOX Provides Current Update on Key Company Developments GlobeNewswire Inc

Jul 20, 2020

04:25PM EDT Nymox Pharmaceutical Entered Into Sales Agreement With Alliance Global Partners As Sales Agent Benzinga

Share